A migraine-blocking antibody tested in children as young as 6

NCT ID NCT03539393

AVAILABLE Symptom relief Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This program provides fremanezumab, an injectable antibody that blocks a protein linked to migraine, to children aged 6 to 17 with chronic or episodic migraine. Participants must have completed a prior Teva-sponsored study. The goal is to see whether continued treatment can safely reduce migraine attacks in this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fremanezumab, an injectable antibody that blocks a migraine-related protein
What this could lead to: If it works, this could offer a treatment option for children with hard-to-treat migraine who have few approved therapies.
What could go wrong: This is a small, open-label program without a placebo group, so results may not prove effectiveness. Side effects include injection-site reactions and possible allergic responses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MIGRAINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MIGRAINE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.